February 2022

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

Advances in technology and research have pushed the field to the brink of a revolutionary era of treatment.

Heterogeneity suggests that identifying different types of Parkinson disease could improve patient management, the understanding of underlying disease mechanisms, and the development of target-specific therapies.

With one-third of the 3.4 million US patients with epilepsy currently experience drug-resistant epilepsy, creating an urgent need for novel intervention strategies, such as stimulation approaches.

In a time when complex medical communication to the public is on display, the need to ensure patient comprehension is of utmost importance for vascular neurologists.

The phase 4 study will evaluate the efficacy and safety of once-monthly injectable galcanezumab compared with every-other-day rimegepant taken orally.

Expert neurologist and sleep specialist Chris Winter, MD, provides a practical outlook on the identification and management of narcolepsy and excessive daytime sleepiness.

Although we have entered the age of genetically targeted therapies in the neuromuscular clinic, there are many unresolved clinical, economic, and ethical questions that require extensive further research.